ESR1 and breast cancer: Therefore, and although the combination TMCG/DIPY was found to be effective on MDA-MB-231, an ERα negative breast cancer cell line, we were interested in investigate whether this combination was also active on tamoxifen-resistant cell lines developed by a prolonged exposition to this drug (acquired resistance).